Literature DB >> 31802216

Prediction of axillary response by monitoring with ultrasound and MRI during and after neoadjuvant chemotherapy in breast cancer patients.

Na Lae Eun1, Eun Ju Son1, Hye Mi Gweon1, Jeong-Ah Kim1, Ji Hyun Youk2.   

Abstract

PURPOSE: To investigate whether monitoring with ultrasound and MR imaging before, during and after neoadjuvant chemotherapy (NAC) can predict axillary response in breast cancer patients.
MATERIALS AND METHODS: A total of 131 breast cancer patients with clinically positive axillary lymph node (LN) who underwent NAC and subsequent surgery were enrolled. They had ultrasound and 3.0 T-MR examinations before, during and after NAC. After reviewing ultrasound and MR images, axillary LN features and tumour size (T size) were noted. According to LN status after surgery, imaging features and their diagnostic performances were analysed.
RESULTS: Of the 131 patients, 60 (45.8%) had positive LNs after surgery. Pre-NAC T size at ultrasound and MR was different in positive LN status after surgery (p < 0.01). There were significant differences in mid- and post-NAC number, cortical thickness (CxT), T size and T size reduction at ultrasound and mid- and post-NAC CxT, hilum, T size and T size reduction, and post-NAC ratio of diameter at MR (p < 0.03). On multivariate analysis, pre-NAC MR T size (OR, 1.03), mid-NAC ultrasound T size (OR, 1.05) and CxT (OR, 1.53), and post-NAC MR T size (OR, 1.06) and CxT (OR, 1.64) were independently associated with positive LN (p < 0.004). Combined mid-NAC ultrasound T size and CxT showed the best diagnostic performance with AUC of 0.760.
CONCLUSION: Monitoring ultrasound and MR axillary LNs and T size can be useful to predict axillary response to NAC in breast cancer patients. KEY POINTS: • Monitoring morphologic features of LNs is useful to predict axillary response. • Monitoring tumour size by imaging is useful to predict axillary response. • The axillary ultrasound during NAC showed the highest diagnostic performance.

Entities:  

Keywords:  Breast cancer; Lymph nodes; Magnetic resonance imaging; Neoadjuvant therapy; Ultrasound

Mesh:

Year:  2019        PMID: 31802216     DOI: 10.1007/s00330-019-06539-4

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  25 in total

1.  Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance).

Authors:  Judy C Boughey; Karla V Ballman; Kelly K Hunt; Linda M McCall; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Huong T Le-Petross
Journal:  J Clin Oncol       Date:  2015-02-02       Impact factor: 44.544

2.  Axillary Pathologic Complete Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Breast Cancer Patients: A Predictive Model Integrating the Imaging Characteristics of Ultrasound Restaging with Known Clinicopathologic Characteristics.

Authors:  Won Hwa Kim; Hye Jung Kim; Ho Yong Park; Ji Young Park; Yee Soo Chae; So Mi Lee; Seung Hyun Cho; Kyung Min Shin; Sang Yub Lee
Journal:  Ultrasound Med Biol       Date:  2018-12-17       Impact factor: 2.998

Review 3.  Noninvasive nodal restaging in clinically node positive breast cancer patients after neoadjuvant systemic therapy: a systematic review.

Authors:  R J Schipper; M Moossdorff; R G H Beets-Tan; M L Smidt; M B I Lobbes
Journal:  Eur J Radiol       Date:  2014-10-13       Impact factor: 3.528

4.  Axillary Ultrasound Before Neoadjuvant Chemotherapy for Breast Cancer: Don't Discount the Benefits Yet!

Authors:  Theresa L Schwartz; Julie A Margenthaler
Journal:  Ann Surg Oncol       Date:  2017-01-17       Impact factor: 5.344

5.  Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype.

Authors:  Rosalind P Candelaria; Roland L Bassett; William Fraser Symmans; Maheshwari Ramineni; Stacy L Moulder; Henry M Kuerer; Alastair M Thompson; Wei Tse Yang
Journal:  Oncologist       Date:  2017-03-17

6.  A Predictive Model for Axillary Node Pathologic Complete Response after Neoadjuvant Chemotherapy for Breast Cancer.

Authors:  Olga Kantor; Lynn McNulty Sipsy; Katharine Yao; Ted A James
Journal:  Ann Surg Oncol       Date:  2018-01-24       Impact factor: 5.344

7.  Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.

Authors:  Manfred Kaufmann; Gunter von Minckwitz; Elefhterios P Mamounas; David Cameron; Lisa A Carey; Massimo Cristofanilli; Carsten Denkert; Wolfgang Eiermann; Michael Gnant; Jay R Harris; Thomas Karn; Cornelia Liedtke; Davide Mauri; Roman Rouzier; Eugen Ruckhaeberle; Vladimir Semiglazov; W Fraser Symmans; Andrew Tutt; Lajos Pusztai
Journal:  Ann Surg Oncol       Date:  2011-12-23       Impact factor: 5.344

8.  Diagnostic performance of breast ultrasonography and MRI in the prediction of lymph node status after neoadjuvant chemotherapy for breast cancer.

Authors:  Su Min Ha; Joo Hee Cha; Hak Hee Kim; Hee Jung Shin; Eun Young Chae; Woo Jung Choi
Journal:  Acta Radiol       Date:  2017-03-28       Impact factor: 1.990

9.  Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.

Authors:  Thorsten Kuehn; Ingo Bauerfeind; Tanja Fehm; Barbara Fleige; Maik Hausschild; Gisela Helms; Annette Lebeau; Cornelia Liedtke; Gunter von Minckwitz; Valentina Nekljudova; Sabine Schmatloch; Peter Schrenk; Annette Staebler; Michael Untch
Journal:  Lancet Oncol       Date:  2013-05-15       Impact factor: 41.316

10.  Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.

Authors:  Tina J Hieken; Judy C Boughey; Katie N Jones; Sejal S Shah; Katrina N Glazebrook
Journal:  Ann Surg Oncol       Date:  2013-07-12       Impact factor: 5.344

View more
  5 in total

1.  Assessment of preoperative axillary nodal disease burden: breast MRI in locally advanced breast cancer before, during and after neoadjuvant endocrine therapy.

Authors:  Jürgen Geisler; Jonn Terje Geitung; Joana Reis; Joao Boavida; Hang T Tran; Marianne Lyngra; Laurens Cornelus Reitsma; Hossein Schandiz; Woldegabriel A Melles; Kjell-Inge Gjesdal
Journal:  BMC Cancer       Date:  2022-06-25       Impact factor: 4.638

2.  Combining conventional ultrasound and sonoelastography to predict axillary status after neoadjuvant chemotherapy for breast cancer.

Authors:  Jia-Xin Huang; Shi-Yang Lin; Yan Ou; Cai-Gou Shi; Yuan Zhong; Ming-Jie Wei; Xiao-Qing Pei
Journal:  Eur Radiol       Date:  2022-04-02       Impact factor: 7.034

3.  Accuracy of ultrasonographic changes during neoadjuvant chemotherapy to predict axillary lymph node response in clinical node-positive breast cancer patients.

Authors:  Zhuoxuan Li; Yiwei Tong; Xiaosong Chen; Kunwei Shen
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

4.  Application of conventional ultrasonography combined with contrast-enhanced ultrasonography in the axillary lymph nodes and evaluation of the efficacy of neoadjuvant chemotherapy in breast cancer patients.

Authors:  Xue Han; Shiyang Jin; Huajing Yang; Jinxing Zhang; Zhenfeng Huang; Jiguang Han; Chuan He; Hongyan Guo; Yue Yang; Ming Shan; Guoqiang Zhang
Journal:  Br J Radiol       Date:  2021-09-01       Impact factor: 3.629

5.  Efficacy of US, MRI, and F-18 FDG-PET/CT for Detecting Axillary Lymph Node Metastasis after Neoadjuvant Chemotherapy in Breast Cancer Patients.

Authors:  Umit Turan; Murat Aygun; Berna Bozkurt Duman; Aygül Polat Kelle; Yeliz Cavus; Zeynel Abidin Tas; Ahmet Baris Dirim; Oktay Irkorucu
Journal:  Diagnostics (Basel)       Date:  2021-12-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.